Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin m after treatment of patients with waldenström macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 2, 2013, Pages 250-252

  Tripsas, Christina K ^a   Patterson, Christopher J ^a   Uljon, Sacha N ^b,c   Lindeman, Neal I ^b,c   Turnbull, Barry ^d   Treon, Steven P ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Biobridges Inc   (United States)

Author keywords

Immunoglobulin M; Response assessment; Waldenstr m macroglobulinemia

Indexed keywords

IMMUNOGLOBULIN M; M PROTEIN; RITUXIMAB;

ADULT; AGED; BONE MARROW; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; SPLENOMEGALY; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PROTEIN ELECTROPHORESIS; HUMANS; IMMUNOGLOBULIN M; MIDDLE AGED; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 84877316072     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.04.002     Document Type: Conference Paper

References (14)

1. R.G. Owen, S.P. Treon, A. Al-Katib Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia Semin Oncol 30 2003 110 115 (Pubitemid 36506291)
2. S.H. Swerdlow, E. Campo, N.L. Harris WHO classification of tumours of haematopoietic and lymphoid tissues 2008 IARC Lyon, France 194-5
3. N.L. Harris, E.S. Jaffe, J. Diebold The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical Advisory Committee meeting-Airlie house, Virginia, November, 1997 J Clin Oncol 17 1999 3835 3849
4. N.L. Harris, H. Stein, S.E. Coupland New approaches to lymphoma diagnosis Hematology Am Soc Hematol Educ Programs 2001 194 220
5. S.P. Treon How I treat Waldenström macroglobulinemia Blood 114 2009 2375 2385
6. R.A. Kyle, P.R. Greipp, M.A. Gertz Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil Br J Haematol 108 2000 737 742 (Pubitemid 30304504)
7. E. Kimby, S.P. Treon, A. Anagnostopoulos Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia Clin Lymphoma Myeloma 6 2006 380 383
8. S.P. Treon, G. Yang, C. Hanzis Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia Br J Haematol 154 2011 223 228
9. R.G. Owen, R.A. Kyle, M.J. Stone Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop Br J Haematol 160 2013 171 176
10. S.P. Treon, C. Hanzis, R.J. Manning Maintenance rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen Br J Haematol 154 2011 357 362
11. S. Uljon, S.P. Treon, C.K. Tripsas Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenstrom's macroglobulinemia Clin Lymphoma Myeloma Leuk 13 2013 247 249
12. D.L. Murray, E. Ryu, M.R. Snyder Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry Clin Chem 55 2009 1523 1529
13. S.P. Treon, L. Xu, G. Yang MYD88 L265P somatic mutation in Waldenström's macroglobulinemia N Engl J Med 367 2012 826 833
14. L. Xu, Z.R. Hunter, G. Yang MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction Blood 121 2013 2051 2058